Sincalide
Also known as: C-CCK-8, Caerulein analog, CCK-8, CCK-8S, Cholecystokinin octapeptide, Kinevac
Source Sincalide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Synthetic octapeptide (CCK-8) used diagnostically to assess gallbladder ejection fraction and stimulate pancreatic secretion; administered intravenously
Mechanism of Action
Agonist of CCK-A (CCK1) and CCK-B (CCK2) receptors, stimulating gallbladder contraction and pancreatic enzyme secretion
Routes of Administration
Goals & Uses
- Pancreatic secretion stimulationResearchModerate
- Assessment of gallbladder ejection fractionDiagnosticHigh
- Acceleration of small bowel barium transitDiagnostic ImagingModerate
- Stimulation of pancreatic enzyme secretionDiagnosticHigh
- Gallbladder contraction for cholecystographyDiagnostic ImagingHigh
- Research tool for CCK receptor studiesResearchHigh
- Gallbladder ejection fraction testingDiagnosticHigh
Contraindications
- Intestinal obstructionGastrointestinalModerate
- Hypersensitivity to sincalide or CCK analogsAllergyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Known hypersensitivity to sincalideAllergyHigh
- Severe acute pancreatitisGastrointestinalModerate
Adverse Effects
- Abdominal discomfort/crampingGastrointestinalCommon
- HypotensionCardiovascularUncommonLow blood pressure
- FlushingVascularCommonWarmth and redness of the skin
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalUncommonForceful expulsion of stomach contents
- DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
- Abdominal crampingGastrointestinalCommon
Drug Interactions
- Anticholinergic agentsLow
- Opioid analgesicsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Patients with suspected acute pancreatitisGastrointestinalRelative
Regulatory Status
- European UnionInvestigationalNot widely marketed; used in clinical studies
- United StatesApprovedApproved: Gallbladder ejection fraction testing, Pancreatic function testingDiagnostic use only
- United KingdomUnknownLimited marketing authorization data available for the UK.
Approved by the FDA for diagnostic use. Administered intravenously under medical supervision. Not for therapeutic use.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Sincalide?
Synthetic octapeptide (CCK-8) used diagnostically to assess gallbladder ejection fraction and stimulate pancreatic secretion; administered intravenously
What is Sincalide used for?
Sincalide is educationally associated with: Pancreatic secretion stimulation, Assessment of gallbladder ejection fraction, Acceleration of small bowel barium transit, Stimulation of pancreatic enzyme secretion, Gallbladder contraction for cholecystography, Research tool for CCK receptor studies, Gallbladder ejection fraction testing. Educational only — not medical advice.
How is Sincalide administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Sincalide?
Reported adverse effects include: Abdominal discomfort/cramping, Hypotension, Flushing, Nausea, Vomiting, Dizziness, Abdominal cramping. This list is not exhaustive — consult a qualified clinician.
Who should avoid Sincalide?
Recorded contraindications: Intestinal obstruction, Hypersensitivity to sincalide or CCK analogs, Pregnancy, Known hypersensitivity to sincalide, Severe acute pancreatitis. Consult a qualified clinician before use.